PMID- 23305331
OWN - NLM
STAT- MEDLINE
DCOM- 20130903
LR  - 20191210
IS  - 1478-3231 (Electronic)
IS  - 1478-3223 (Linking)
VI  - 33
IP  - 4
DP  - 2013 Apr
TI  - Hepatocellular carcinoma treated with sorafenib: early detection of treatment 
      response and major adverse events by contrast-enhanced US.
PG  - 605-15
LID - 10.1111/liv.12098 [doi]
AB  - BACKGROUND & AIMS: Early prediction of tumour response and major adverse events 
      (AEs), especially liver failure, in patients with hepatocellular carcinoma (HCC) 
      is essential for maximizing the clinical benefits of sorafenib. To evaluate the 
      usefulness of dynamic contrast-enhanced ultrasound (DCE-US) for the early 
      prediction of tumour response and major AEs in HCC patients. METHODS: 
      Thirty-seven HCC patients were started on a reduced dosage of sorafenib, 
      subsequently increased to the standard dosage. Tumour response at 1 month was 
      assessed by CT using the Response Evaluation Criteria in Solid Tumors (RECIST). 
      Major AEs were defined as grade 3 or higher. DCE-US was performed before 
      treatment (day 0) and on days 7, 14 and 28. Changes in perfusion parameters in 
      the tumour and liver parenchyma between day 0 and later time points were compared 
      between treatment responders and nonresponders based on RECIST and between 
      patients who experienced major AEs and those who did not. Tumour results were 
      also compared with progression-free survival (PFS) and overall survival (OS). 
      RESULTS: Tumour perfusion parameters based on the area under the time-intensity 
      curve (AUC) were statistically significant, with AUC during washin on day 14, the 
      most relevant for tumour response (P = 0.0016) and AUC during washin on day 7, 
      the most relevant for both PFS (P = 0.009) and OS (P = 0.037). A decrease in 
      total AUC between days 0 and 7 in the liver parenchyma was strongly correlated 
      with major AEs (P = 0.0002). CONCLUSION: DCE-US may be useful for the early 
      prediction of tumour response and major AEs in patients with HCC.
CI  - (c) 2013 John Wiley & Sons A/S.
FAU - Sugimoto, Katsutoshi
AU  - Sugimoto K
AD  - Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, 
      Japan. sugimoto@tokyo-med.ac.jp
FAU - Moriyasu, Fuminori
AU  - Moriyasu F
FAU - Saito, Kazuhiro
AU  - Saito K
FAU - Rognin, Nicolas
AU  - Rognin N
FAU - Kamiyama, Naohisa
AU  - Kamiyama N
FAU - Furuichi, Yoshihiro
AU  - Furuichi Y
FAU - Imai, Yasuharu
AU  - Imai Y
LA  - eng
PT  - Journal Article
PT  - Validation Study
DEP - 20130111
PL  - United States
TA  - Liver Int
JT  - Liver international : official journal of the International Association for the 
      Study of the Liver
JID - 101160857
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Contrast Media)
RN  - 0 (Ferric Compounds)
RN  - 0 (Oxides)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Sonazoid)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
RN  - E1UOL152H7 (Iron)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/adverse effects/*therapeutic use
MH  - Area Under Curve
MH  - Carcinoma, Hepatocellular/blood supply/*diagnostic imaging/*drug 
      therapy/mortality
MH  - *Contrast Media
MH  - Disease-Free Survival
MH  - Female
MH  - *Ferric Compounds
MH  - Humans
MH  - *Iron
MH  - Kaplan-Meier Estimate
MH  - Liver Neoplasms/blood supply/*diagnostic imaging/*drug therapy/mortality
MH  - Male
MH  - Middle Aged
MH  - Niacinamide/adverse effects/*analogs & derivatives/therapeutic use
MH  - *Oxides
MH  - Perfusion Imaging/*methods
MH  - Phenylurea Compounds/adverse effects/*therapeutic use
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Protein Kinase Inhibitors/adverse effects/*therapeutic use
MH  - Reproducibility of Results
MH  - Sorafenib
MH  - Time Factors
MH  - Tomography, X-Ray Computed
MH  - Treatment Outcome
MH  - Ultrasonography
EDAT- 2013/01/12 06:00
MHDA- 2013/09/04 06:00
CRDT- 2013/01/12 06:00
PHST- 2012/07/25 00:00 [received]
PHST- 2012/11/22 00:00 [accepted]
PHST- 2013/01/12 06:00 [entrez]
PHST- 2013/01/12 06:00 [pubmed]
PHST- 2013/09/04 06:00 [medline]
AID - 10.1111/liv.12098 [doi]
PST - ppublish
SO  - Liver Int. 2013 Apr;33(4):605-15. doi: 10.1111/liv.12098. Epub 2013 Jan 11.